🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Tenet healthcare director sells $185k in company stock

Published 06/12/2024, 08:03 PM
THC
-

In a recent transaction on June 10, Richard W. Fisher, a director at Tenet Healthcare Corp (NYSE:THC), sold 1,400 shares of the company's common stock at an average price of $132.24 per share, totaling approximately $185,136.

The sale was disclosed in a filing with the Securities and Exchange Commission. Following the transaction, Fisher's holdings in Tenet Healthcare decreased to 16,227 shares of common stock, directly owned. The transaction reflects a routine adjustment in Fisher's investment portfolio.

Tenet Healthcare Corp, based in Dallas, Texas, operates as a diversified healthcare services company. The company, incorporated in Nevada, is known for providing healthcare services through its general medical and surgical hospitals.

Investors often monitor insider sales as they can provide insights into an executive's view of the company's current valuation and future prospects. However, such transactions can also be part of personal financial management, including diversification and liquidity needs.

The disclosed transaction was signed by Chad J. Wiener as Attorney-in-Fact for Richard W. Fisher on June 12, as noted in the SEC filing. The details of the sale are now publicly available for shareholders and potential investors to review.

In other recent news, Tenet Healthcare has been in the spotlight following a series of positive analyst reviews and strong first-quarter financials. Deutsche Bank upgraded Tenet Healthcare's stock, citing a revised valuation approach and raising its price target to $150. The bank's revised valuation is based on an 8.3 times multiple applied to its 2025 EBITDA projections for the company, a change from the earlier blended valuation method.

Similarly, Mizuho Securities increased its price target for Tenet Healthcare to $130, following the company's robust Q1 performance. Mizuho's revised price target reflects a positive stance on Tenet Healthcare's strategic actions, including its share repurchase program and significant deleveraging efforts. RBC Capital also raised its price target for Tenet Healthcare to $136, signaling confidence in the company's ability to capitalize on current market conditions.

Tenet Healthcare recently reported strong Q1 financials, with a notable 23% increase in consolidated adjusted EBITDA, reaching $1.02 billion. The company's net operating revenues stood at $5.4 billion. Following the sale of nine hospitals, Tenet successfully reduced its leverage ratio by using the $4 billion in pretax proceeds to retire debt. With these positive trends, Tenet has increased its full-year adjusted EBITDA forecast to between $3.5 billion and $3.7 billion.

These recent developments underscore the healthcare company's potential for continued success, as it navigates through the financial year. Investors are keeping a close eye on Tenet Healthcare as it strives to meet the heightened expectations set forth by these revised price targets.

InvestingPro Insights

In light of the recent insider transaction at Tenet Healthcare Corp (NYSE:THC), investors might find the following InvestingPro data and tips particularly insightful:

InvestingPro Data:

  • The company's market capitalization stands at a robust $13.75 billion.
  • Tenet Healthcare boasts a very attractive P/E ratio of 5.47, indicating the stock may be undervalued relative to earnings.
  • The stock is trading near its 52-week high, with a price percentage of 98.88% of the peak value.

InvestingPro Tips:

  • Tenet Healthcare has a perfect Piotroski Score of 9, suggesting strong financial health.
  • With management aggressively buying back shares and a high shareholder yield, the company is demonstrating a commitment to returning value to its investors.

These metrics and strategic moves by the company's management could be particularly relevant for investors assessing the significance of the insider sale. Additionally, the company's strong performance and potential undervaluation highlighted by the low P/E ratio might offer a different perspective on the recent sale by director Richard W. Fisher.

For more in-depth analysis and additional InvestingPro Tips on Tenet Healthcare Corp, investors can visit https://www.investing.com/pro/THC. There are 14 more tips available, providing a comprehensive overview of the company's financial health and market position. Interested readers can also take advantage of a special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.